https://doi.org/10.1038/s41540-020-00145-7
C
Chi‐Chung Li
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
92
Papers
3.0K
Citations
27
h-index
46
i10-index
Chi‐Chung Li is an academic researcher. The author has contributed to research in topics: CAR-T cell therapy research & Monoclonal and Polyclonal Antibodies Research & Lymphoma Diagnosis and Treatment. The author has an h-index of 27, co-authored 79 publications.
ORCID: 0000-0002-9590-3450Papers by this author
worksMitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling
2020 · npj Systems Biology and Applications · 110 citations
A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities
2016 · Cancer Chemotherapy and Pharmacology · 47 citations
https://doi.org/10.1007/s00280-015-2931-4
Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
2024 · Clinical Cancer Research · 31 citations
https://doi.org/10.1158/1078-0432.ccr-24-2247
A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
2024 · Clinical Pharmacology & Therapeutics · 6 citations
https://doi.org/10.1002/cpt.3445
Cytokine Release Syndrome: Trends with T Cell Engaging Bispecifics from a Systematic Review of Licensing Applications
2024 · Blood · 2 citations
https://doi.org/10.1182/blood-2024-193916
P0119 PTP4A3 overexpression predicts clinical aggressiveness in urothelial carcinoma
2014 · European Journal of Cancer · 0 citations
https://doi.org/10.1016/j.ejca.2014.03.163
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat